High level expression of a human rabies virus-neutralizing monoclonal antibody by a rhabdovirus-based vector.
Publication/Presentation Date
6-1-2001
Abstract
Humans exposed to rabies virus must be promptly treated by passive immunization with anti-rabies antibody and active immunization with rabies vaccine. Currently, antibody prepared from pooled human serum or from immunized horses is utilized. However, neither of these reagents are readily available, entirely safe, or consistent in their biological activity. An ideal reagent would consist of a panel of human monoclonal antibodies. Such antibodies are now available, their only drawback being the cost of production. Using recombinant technology, we constructed a rabies virus-based vector which expresses high levels (approximately 60 pg/cell) of rabies virus-neutralizing human monoclonal antibody. The vector is a modified vaccine strain of rabies virus in which the rabies virus glycoprotein has been replaced with a chimeric vesicular stomatitis virus glycoprotein, and both heavy and light chain genes encoding a human monoclonal antibody have been inserted. This recombinant virus can infect a variety of mammalian cell lines and is non-cytolytic, allowing the use of cell culture technology routinely employed to produce rabies vaccines.
Volume
252
Issue
1-2
First Page
199
Last Page
206
ISSN
0022-1759
Published In/Presented At
Morimoto, K., Schnell, M. J., Pulmanausahakul, R., McGettigan, J. P., Foley, H. D., Faber, M., Hooper, D. C., & Dietzschold, B. (2001). High level expression of a human rabies virus-neutralizing monoclonal antibody by a rhabdovirus-based vector. Journal of immunological methods, 252(1-2), 199–206. https://doi.org/10.1016/s0022-1759(01)00353-2
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
11334980
Department(s)
Administration and Leadership
Document Type
Article